SCHEMBL20939594

SCHEMBL20939594

CC(C)(C)OC(=O)N1CCc2c(N)cc(Cl)cc21

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR1H2 P55055 1/20 0.39
▸ GPR119 Q8TDV5 3/20 0.39
▸ KDM1A O60341 1/20 0.39
▸ UCHL1 P09936 3/20 0.39
▸ USP30 Q70CQ3 1/20 0.39
▸ STS P08842 3/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ ESR2 Q92731 1/20 0.37
▸ ADORA1 P30542 1/20 0.37
▸ HDAC1 Q13547 1/20 0.36
▸ HDAC6 Q9UBN7 1/20 0.36
▸ NOTUM Q6P988 1/20 0.36
▸ CHRM4 P08173 1/20 0.36
▸ DRD2 P14416 1/20 0.36
▸ HTR7 P34969 1/20 0.36
▸ SMARCA2 P51531 1/20 0.35
▸ SMARCA4 P51532 1/20 0.35
▸ PBRM1 Q86U86 1/20 0.35
▸ MPO P05164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8109798 0.82 GPR119 (0.40) GPR119KDM1AUCHL1USP30STS
SCHEMBL8111090 0.81 UCHL1 (0.45) NR1H2GPR119KDM1AUCHL1USP30
SCHEMBL256728 0.78 UCHL1 (0.51) NR1H2GPR119KDM1AUCHL1HDAC1
SCHEMBL21166288 0.76 GPR119 (0.39) NR1H2GPR119KDM1AUCHL1USP30
SCHEMBL26124057 0.76 NOTUM (0.48) NR1H2GPR119KDM1AUCHL1USP30
SCHEMBL20939733 0.75 MAP3K14 (0.38) KMT2ANOTUM
SCHEMBL20939644 0.74 MAP3K14 (0.40) MEN1KMT2ANOTUMDRD2KDM4E
SCHEMBL27975558 0.73 NOTUM (0.65) GPR119ESR2NOTUM
SCHEMBL868725 0.73 NOTUM (0.65) GPR119KDM1AUCHL1STSHDAC1
SCHEMBL31161834 0.72 UCHL1 (0.48) NR1H2GPR119KDM1AUCHL1USP30

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11186589-B2 Cyanoindoline derivatives as NIK inhibitors JANSSEN PHARMACEUTICA NV (BE) 2021-11-30 — — US disclosed
US-20210032267-A1 CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2021-02-04 — — US disclosed
EP-3478673-B1 CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2020-09-16 — — EP disclosed
US-20190119299-A1 CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2019-04-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210032267-A1 CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS MAP3K14, NFKBIA, MAP3K15 NR1H2 681/4885GPR119 695/4885KDM1A 1952/4885
US-20190119299-A1 CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS NFKBIA, IKBKG, IKBKB NR1H2 1193/4885GPR119 1059/4885KDM1A 1827/4885
US-11186589-B2 Cyanoindoline derivatives as NIK inhibitors MAP3K14, NFKBIA, MAP3K15 NR1H2 681/4885GPR119 695/4885KDM1A 1952/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback